Your invitation to attend the CRS Product Development Forum - Poorly Soluble Drugs

CRS Product Development Forum – Poorly Soluble Drugs

January 27-28, 2011
Doral Golf Resort & Spa
Miami, Florida U.S.A.

You are invited to attend an informative two-day program devoted exclusively to the topic of poorly soluble drugs; CRS Product Development Forum – Poorly Soluble Drugs. January 27-28, 2011, Doral Golf Resort & Spa, Miami, Florida.

Who should attend? People from all fields involved in the development of drugs including receptor targets; drug discovery; ADME; pre-formulation (and formulation); human physiology; and in-vitro, in-silico, and in-vivo models and clinical trials (including special populations).

Understanding the Challenges of Poorly Soluble Drugs
Poorly soluble compounds compose an increasingly large percentage of the NCEs being developed today. These substances have great potential, but they present many challenges to effective delivery, including decreased bioavailability and inter-patient variability. Compounding these issues, many of the existing paradigms for drug development do not apply to poorly soluble compounds.

Unlocking the Door to New Paradigms in Drug Delivery
In spite of these challenges, the potential of poorly soluble drugs is too great to be ignored. By developing new formulation strategies, better technologies for enhancing drug solubility, and more efficient methods of delivery, we can extend the life cycle of established low-solubility drugs, increase the number of poorly soluble drug candidates for development, and deliver highly effective and economically efficient treatments to the patient.

This two-day forum will expose those involved in the discrete parts of the process to state-of-the-art information in all areas. With greater understanding of the full spectrum of problems, we can unlock the door to new paradigms in the development and delivery of poorly soluble drugs, to the benefit of patients and the industry. Register now!

This year, the CRS Product Development Forum is co-located with the 15th Annual Drug Delivery Partnerships, January 26-28, 2011, also at Doral. Ask about registration discounts when registering for both meetings.

PROGRAM HIGHLIGHTS

Plenary Topics
Pros & Cons of BSC in Drug Discovery
Formulation Strategies for Delivering Poorly Soluble Actives
Formulation Strategies with Emphasis on Class 4 Compounds—Good Case Stories
Lipolysis Modeling and Food Effect

Session Topics
Human GI Physiology
In-Vivo Studies of Absorption of Poorly Soluble Actives
Solution/Semi-solid Formulation Approaches
In-Vitro Methodologies
Mid- to Late-State Development (Phase II and Beyond)

Click here to view the complete program with confirmed speakers.

CALL FOR PAPERS
October 29, 2010, is the last day to submit your abstract.

REGISTRATION
The registration deadline is January 4, 2011. Register today!

Share this article with your social network, just click below to share now!

Share |

Biocon and Pfizer team up to promote insulin biosimilar

Biocon, Asia's leading biotechnology company, will be teaming up with Pfizer to promote the insulin biosimilars Glargine, Aspart and Lispro throughout the world according to Topinews. This partnerships will represent the companies working together worldwide on manufacturing, marketing and research. Biocon will receive $200 million up front and payments of $150 million in regulatory payments.

David Simmons, president and general manager of Pfizer’s Established Products Business Unit, stated:
"We are excited to join forces with Biocon in the battle against the disease and economic burden that diabetes poses to global health. Our alliance with Biocon will enable the delivery of biosimilar insulin products, providing attractive, cost-effective treatment options to more diabetes patients."

Share this article with your social network, just click below to share now!

Share |

Consortium close to human trials of HIV vaccines

The first human trial of the HIV vaccine candidate designed by Los Alamos National Laboratory researcher Bette Korber is part of an international team of investigators will fight the genetic diversity of the vaccine. Tests on animals have shown early success, and the vaccine is designed to protect against a variety of HIV strands. Read the full press release here.

According to Korber, "HIV's diversity is vast, and the mosaic gene design represents a novel vaccine design to directly tackle HIV diversity in human clinical trials. Based on computational models, mosaic vaccines were predicted to perform better than natural HIV genes; experimental studies in animals, which directly compared mosaic to natural vaccines, supported that prediction. We are excited to test this concept in humans."

Share this article with your social network, just click below to share now!

Share |

Pfizer buying King Pharmaceuticals

Pfizer recently announced it's purchase of King Pharmaceuticals for #3.6 billion. Big pharma continues to buy small Pharma firms looking to acquire new products to their pipelines.

King's main products include, pain drugs, including painkillers designed to be resistant to abuse, and EpiPen, a pre-filled injection to treat allergic reactions. Pfizer has stated that they will cut $200 million in costs. News Observer has the full story.

Share this article with your social network, just click below to share now!

Share |

Vaccine safety key worry for parents

According to MedPage Today, vaccine and drug safety is the top concern among parents when looking at their children's safety in connection with medical needs and medication.

Matthew Davis, MD, associate professor of pediatrics and internal medicine at the University of Michigan in Ann Arbor, who conducted a poll in connection with C.S. Mott Children's National Poll on Children's Health, stated:
"Parental concerns about the safety of vaccines have increased markedly over the last decade, due to alleged but later disproven links between vaccines and autism and related concerns about mercury and other preservatives used in vaccines."

What is your standpoint on the amount of research done for the safety of vaccines?

This blog is co-posted with The Drug Delivery Blog.

Share this article with your social network, just click below to share now!

Share |

New vaccine to protect against small pox and anthrax

A new dual vaccine, protecting against smallpox and anthrax, has been created. It will protect those who receive it from potential terror attacks according to BioPrepWatch. The vaccine can be freeze-dried and stockpiled so that it can be accessed should a rapid vaccination of the population need to take place.

Liyanage Perera of the U.S. National Cancer Institute and his colleagues wrote, stated:
"Although licensed vaccines are available for both smallpox and anthrax, because of inadequacies associated with each of these vaccines, serious concerns remain as to the deployability of these vaccines, especially in the aftermath of a bioterror attack involving these pathogens."

Share this article with your social network, just click below to share now!

Share |